Our impact
Our companies
Supply the life sciences sector with created assets and stimulate the growth of entrepreneurial activities in life sciences in Canada
ExCellThera
ExCellThera is a late-stage biotechnology company providing molecules and bioengineering solutions to develop the best cell and gene therapies. It has exclusive rights to the patented UM171 molecule, which stimulates the expansion of stem cells to treat people with leukemia and other blood cancers. Over a hundred patients have been treated with UM171-amplified cell therapy in clinical trials in the United States, Europe and Canada. UM171 cell therapy has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, as well as Orphan Drug Designation, Advanced Therapy Medicinal Product (ATMP) classification and Priority Medicinal Product (PRIME) designation from the EMA. UM171 cell therapy has successfully completed Phase 2 trials in acute leukemia and high- and very high-risk myelodysplasia, and a Phase 3 trial is now planned for 2025.
Epitopea
Epitopea is a transatlantic cancer immunotherapeutics company (Montreal, Canada and Cambridge, UK) developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as CryptigenTM TSAs, Epitopea is backed by leading life science investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, Investissement Québec, adMare BioInnovations, Jonathan Milner, the Harrington Discovery Institute, IRICoR and Novateur Ventures. To date the company has raised financing of more than USD $45 million.
RejuvenRx
A spin-off from ExCellThera, RejuvenRx is a biotechnology company working on delivering precision therapies to overcome cancer and aging. RejuvenRx is developing its main asset, a series of small molecules promoting tissue regenerative capacity aimed at treating cancers, aging frailty and other diseases.
Drave Therapeutics
Our partners
IRICoR bridges the gap between academic research and business via the pharmaceutical industry and venture capital to accelerate the transformation of drug discovery projects into new therapies.
Biopharmaceuticals
Financial
Academic
